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Abstract 
 
One of the most commonly prescribed lipid lowering medications are statins. In the majority of 
cases, statins are generally well tolerated. In rare instances, statin induced necrotizing 
autoimmune myositis (SINAM) can occur. The following case presents a patient with a fifteen 
year history of simvastatin use who developed SINAM following a motor vehicle accident.  
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Case report 
 
A 71-year old white male with a history of hypertension and hyperlipidemia (treated with 
simvastatin for fifteen years) was seen in the  electromyography (EMG) lab to work up severe 
muscle weakness which he reported began three days after an MVA that occurred three months 
prior.  He also complained of fatigue, but denied dysphagia, rashes, pigmenturia, delayed motor 
milestones when growing up, or family history of neuromuscular disease. The emergency room 
evaluation after his MVA focused on a hypertensive crisis and chest pain, but cardiac workup 
was negative and the patient was discharged. Physical examination prior to the EMG showed 
symmetric proximal weakness in both upper and lower extremities with neck and distal muscle 
strength preserved.  Power was 4/5 in bilateral biceps brachii and triceps brachii, 3/5 in deltoids, 
4-/5 in pectoralis, 3/5 in infraspinatus, and 3/5 in hip flexors.  Reflexes were 1+ throughout with 
absent patellar and achilles reflexes. In all four extremities, sensation remained intact and there 
was no tenderness to palpation. We were unable to assess the patient’s gait due to the extent of 
weakness.  
 
EMG of the right arm and leg showed an acute on chronic myopathic process with evidence of 
irritability of muscle membranes (abundant waning discharges) and diffuse fibrillations including 
in the L4 and C7 paraspinal muscles.  Creatinine phospokinase (CPK) was 11,353, LDH 997, 
AST 405, ALT 512, ESR 27, GGT 130. At this time, a decision to discontinue the patient’s statin 
was made. Jo1 antibody, urine myoglobin, hemoglobin A1c, and myositis panel were negative. 
Limb girdle muscular dystrophy genetic panel was negative.  MRI of the cervical and lumbar 
spine showed diffuse degenerative changes, but no abnormal cord signal. MRI of the left femur 
showed diffuse, abnormal, increased STIR signal and mild fatty atrophy of the thigh musculature 
that was most prominent in the anterior aspect (Figure 1). Light microscopy of the left deltoid 
and quadriceps muscle showed acute myopathy (Figure 2).  Trichrome and H&E stains showed 
mild variation in fiber size. Moderately increased internal nuclei were seen.  ATPase stains 
showed atrophy of both fiber types.  Acid phosphatase stain showed macrophage activity in 
necrotic fibers and connective tissues. 
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Figure 1. MRI with and without of the left femur.  
  
A) T1 sequence showing mixed age edema,  fatty replacement and atrophy in anterior 
hamstrings.  
B) FatSat sequence showing soft tissue fluid and edema with increased heterogeneity.  
 
A )              B )  
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Figure 2. Histochemistry of left quadriceps and deltoid muscle biopsy.  Modified Trichrome, 
Verhoeff Van Gieson, and H&E stains revealed mild variation in fiber size.  
Moderately increased internal nuclei, moderate degenerating, basophilic, and necrotic fibers 
were seen, some round (red arrow).  
ATPase series (pH 9.4 and 4.6) revealed variation in fiber size due to atrophy in both fiber types. 
Non-specific esterase and acid phosphatase reactions reveal macrophages actively in necrotic 
fibers and connective tissue (blue arrow).  
 
 
 
Given the EMG and imaging findings and high suspicion for statin induced necrotizing 
autoimmune myopathy (SINAM), an anti-HMG CoA reductase antibody (HMGCR ab) was sent 
which was high (>200 units).  He was started on empiric corticosteroids (prednisone 1mg/kg). 
He showed improvement in symptoms over the next several days.  One month later he could 
ambulate with a walker, and later strength returned to baseline.  Due to adverse steroid effects 
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prednisone was stopped and patient was started on weekly methotrexate 7.5mg with folic acid, 
which he has tolerated well for over 2 years.  
 
Consent was obtained from the patient. 
 
Discussion 
Statin therapy is commonly prescribed for hyperlipidemia. In 2005, reports estimated that 29.7 
million people were taking statins.4  Approximately 20% of patients taking statins will develop 
myalgias.5  Myotoxicity is usually self-limited, resolving after stopping the offending drug or 
switching from atorvastatin or simvastatin to another statin, which may have a lower propensity 
for inducing symptoms.1    
SINAM is seen in 2-3 out of 100,000 patients taking statins.1 SINAM is characterized by 
progressive proximal muscle weakness, significantly elevated CPK levels (1000-10 000 units/L), 
abnormal EMG and muscle biopsy, and presence of a marker of autoimmune injury called anti-
HMGCoA ab, which has 94.4% sensitivity and 99.3% specificity.2 CPK normalizes and 
symptoms of SINAM improve after administration of immunosuppressants. Symptoms fail to 
resolve by just stopping the statin alone in most cases.2 Some patients with mild weakness from 
SINAM will improve with the cessation of statin alone.2   
Diagnosis of SINAM can be confirmed with serology for the HMGCoA ab, muscle biopsy 
(showing scattered necrotic muscle fibers undergoing myophagocytosis and scant inflammation) 
and EMG (showing increased spontaneous activity, myopathic motor unit action potentials 
(MUAPs) with low amplitude, short duration, polyphasia and early recruitment).3  
Typically, the first line treatment for SINAM is a combination of a steroid with a secondary 
immunosuppressive agent such as methotrexate, azathioprine, or mycophenolate.4 Intravenous 
immunoglobulin (IVIG) is highly efficacious as a monotherapy and in cases of refractory 
SINAM. Our patient was treated for over 2 years with methotrexate and remained stable. Long 
term immunosuppression is suggested in SINAM patients as regenerating muscle fibers in 
positive anti-HMGCR patients have shown upregulation in HMGCR expression, which can 
prolong the autoimmune response.6  
Autoimmune myopathies can occur when genetically susceptible individuals are exposed to 
specific environmental triggers and it was shown that those with HLA-DR11 are predisposed 
towards SINAM.7   It has been shown that around 50% of autoimmune diseases have been 
precipitated by unknown factors.6  Prior to disease onset, studies have shown upwards of 80% of 
patients who develop autoimmune symptoms experienced emotional stress.8  In our patient’s 
case, it is important to consider that the stress from the motor vehicle accident was the triggering 
environmental factor for SINAM, but cannot be definitively proven. The patient’s HLA subtype 
was not tested for, but would also be an important factor to consider testing for in patients with 
SINAM. Although SINAM is a rare complication of statin therapy, it should be considered in 
patients presenting with proximal muscle weakness, elevated CK, and long term statin use.  
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